Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.44 |
| ▸ | ACHE | P22303 | 6/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | SCN4A | P35499 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071793 | 1.00 | BCHE (0.44) | BCHEACHEFAAHDRD2DRD3 | |
| SCHEMBL3081816 | 0.84 | BCHE (0.42) | BCHEACHEDRD2DRD3BACE1 | |
| SCHEMBL3081818 | 0.84 | BCHE (0.42) | BCHEACHEDRD2DRD3BACE1 | |
| SCHEMBL3085547 | 0.81 | DRD2 (0.49) | BCHEACHEDRD2DRD3BACE1 | |
| SCHEMBL3085544 | 0.81 | DRD2 (0.49) | BCHEACHEDRD2DRD3BACE1 | |
| SCHEMBL3088395 | 0.79 | SIGMAR1 (0.47) | BCHEACHEDRD2BACE1SIGMAR1 | |
| SCHEMBL3088399 | 0.79 | SIGMAR1 (0.47) | BCHEACHEDRD2BACE1SIGMAR1 | |
| SCHEMBL3083280 | 0.77 | DRD2 (0.46) | BCHEACHEFAAHDRD2DRD3 | |
| SCHEMBL3083277 | 0.77 | DRD2 (0.46) | BCHEACHEFAAHDRD2DRD3 | |
| SCHEMBL1895967 | 0.73 | DPP4 (0.45) | DRD2DRD3SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | claimed |
| US-7795436-B2 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-14 | — | — | US | disclosed |
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | HTR2B, HTR2C, HTR1A | BCHE 1890/4885ACHE 1059/4885FAAH 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.